This page shows the latest Triple negative breast cancer news and features for those working in and with pharma, biotech and healthcare.
Despite failing in NSCLC, bintrafusp alfa will continue to be evaluated in a number of additional clinical trials across a range of cancer types. ... Merck. The German pharma company also recently initiated monotherapy studies in triple-negative breast
for the treatment of metastatic triple-negative breast cancer (mTNBC).
NBE’s lead candidate, NBE-002, is currently in phase 1 clinical studies for triple negative breast cancer and a number of additional solid tumours. ... Merk &Kollegen’s manufacturing site, which is involved in ATMP-based cancer immunology treatments.
In October, VelosBio announced that it has initiated a phase 2 clinical trial set to investigate VLS-101 for the treatment of patients with solid tumours, including patients with triple-negative ... breast cancer (TNBC), hormone receptor-positive and/or
treatment of metastatic triple-negative breast cancer (mTNBC). ... The ADC is also being studied in an ongoing phase 3 trial in third line HR+/HER2-positive breast cancer, and a registrational phase 2 study in bladder cancer.
As part of this expansive clinical programme, Merck and Seattle Genetics are set to investigate ladiratuzumab vedotin in a number of additional cancer types, including triple-negative breast cancer, hormone ... Tukysa was approved by the US Food and Drug
More from news
Approximately 4 fully matching, plus 67 partially matching documents found.
9. Immunomedic’s sacituzumab govitecan initial target market is metastatic triple negative breast cancer in patients who have failed at least two prior therapies. ... It is approved in the US for the treatment of unresectable or metastatic
The incoming cash will be used by Immunomedics to fund its operations into 2020 including to progress development of sacituzumab govitecan in metastatic triple-negative breast cancer (TNBC), advanced urothelial cancer ... that is highly selective for HER2
triple-negative breast cancer (TNBC), small-cell lung cancer (SCLC), non-small-cell lung cancer (NSCLC) and pancreatic cancer. . ... Acquisition - company. 2, 475. Immunomedics/ Seattle Genetics. IMMU-132 (sacituzumab govitecan), an antibody drug
awarded FDA breakthrough therapy status for advanced melanoma last year, and is being studied in 13 clinical trials across more than 30 types of cancer. Financial terms for these deals were ... BATON studies in colorectal cancer and metastatic triple
More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.
The shocking stats surrounding black women and health outcomes. Alarmingly, although black women are overall less likely to develop breast cancer, they’re 40% more likely to die from it compared ... Black women are at higher risk for a type of
cell carcinoma, Merkel cell carcinoma, and triple-negative breast cancer (TNBC) via chest-wall lesions.8. ... 2018; 15(10):599-616. National Cancer Institute. Surveillance, Epidemiology, and End Results Program.
More from PMHub
Approximately 0 fully matching, plus 2 partially matching documents found.
We're a leading healthcare strategic communications agency helping pharmaceutical companies adapt fast to improve the lives of patients and healthcare...